Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.9
3.3
Journals
Diagnostics
Special Issues
Advances in Nuclear Medicine and Molecular Imaging
share announcement

Advances in Nuclear Medicine and Molecular Imaging

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Medical Imaging and Theranostics".

Deadline for manuscript submissions: closed (31 August 2025) | Viewed by 563

Special Issue Editor

Dr. Gabriele Masselli

E-Mail Website
Guest Editor
Radiology Department, Umberto I Hospital Sapienza University, Rome, Italy
Interests: body MRI; PET/CT; pediatric radiology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue highlights the latest breakthroughs in nuclear medicine and molecular imaging, showcasing cutting-edge technologies and their transformative impact on diagnostics and therapeutics. Key advancements include the development of novel radiotracers that enhance the precision of imaging modalities, such as PET and SPECT, enabling earlier and more accurate detection of diseases, such as cancer, cardiovascular disorders, and neurodegenerative conditions. The integration of artificial intelligence and machine learning into imaging analysis is also explored, offering improved data interpretation and personalized treatment planning. Additionally, this Special Issue delves into theranostics, a rapidly growing field that combines diagnostic imaging with targeted radionuclide therapy, revolutionizing patient care by tailoring treatments to individual molecular profiles. Contributions from leading experts emphasize the interdisciplinary nature of these innovations, bridging radiology, oncology, and computational sciences. This collection not only underscores the current state of the field but also envisions future directions, emphasizing the potential of nuclear medicine and molecular imaging to redefine precision medicine and improve clinical outcomes globally.

Dr. Gabriele Masselli
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer
  • cardiovascular imaging
  • neurodegenerative conditions
  • computed tomography
  • molecular imaging
  • neuroimaging
  • positron emission tomography (PET)
  • single-photon emission computed tomography (SPECT)
  • nuclear medicine
  • molecular imaging
  • theranostics
  • response evaluation

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

10 pages, 968 KB  
Article
Prognostic Value of Automated Bone Scan Index (aBSI) in Patients with mCRPC Undergoing Three vs. Six Cycles of 223Ra Therapy
by Sophie C. Siegmund, Harun Ilhan, Antonia Gerull, Andrei Todica, Marcus Unterrainer, Astrid Delker, Franz Josef Gildehaus, Can D. Aydogdu, Christian G. Stief, Rudolf A. Werner, Lena M. Unterrainer and Mathias J. Zacherl
Diagnostics 2025, 15(16), 2007; https://doi.org/10.3390/diagnostics15162007 - 11 Aug 2025
Viewed by 309
Abstract
Background/Objectives: In patients with metastatic castration-resistant prostate cancer (mCRPC) and osseous metastases only, 223Radium therapy represents a valuable therapeutic option. Bone scintigraphy (BS) is typically performed to assess metastasis load, with the BS-derived automated bone scan index (aBSI) used for response [...] Read more.
Background/Objectives: In patients with metastatic castration-resistant prostate cancer (mCRPC) and osseous metastases only, 223Radium therapy represents a valuable therapeutic option. Bone scintigraphy (BS) is typically performed to assess metastasis load, with the BS-derived automated bone scan index (aBSI) used for response assessment. This study aimed to evaluate the prognostic value of aBSI in patients receiving three or six cycles of 223Ra therapy. Methods: We included patients that were diagnosed with extensive osseous tumor load on BS, had no visceral or nodal metastases, had undergone 223Ra therapy. The aBSI prior to and following three or six cycles of therapy, total tumor volume (TTV), SUVmax, and overall survival were analyzed. Results: This study included 49 mCRPC patients (mean age: 70 ± 9 years) with 42 (85.7%) receiving six and 7 (14.3%) receiving three cycles. After three cycles, the mean aBSI (p = 0.369), TTV (p = 0.902), and SUVmax (p = 0.149) remained unchanged. After six cycles, the mean aBSI (p = 0.247) and TTV (p = 0.784) were unchanged, while SUVmax decreased significantly (p = 0.001). The aBSI did not significantly correlate with the mean aBSI (six cycles: χ2 = 1.823, p = 0.177; three cycles: χ2 = 0.308, p = 0.579). Conclusions: Although quantitative changes in TTV and aBSI did not significantly correlate with each other, their respective absolute values consistently indicated stable disease burden under therapy. This highlights its potential as a useful tool for monitoring disease burden while indicating that aBSI alone is insufficient for predicting overall survival. Full article
(This article belongs to the Special Issue Advances in Nuclear Medicine and Molecular Imaging)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop